BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1252 related articles for article (PubMed ID: 30198439)

  • 1. Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck.
    Łasińska I; Kolenda T; Teresiak A; Lamperska KM; Galus Ł; Mackiewicz J
    Anticancer Agents Med Chem; 2019; 19(3):290-303. PubMed ID: 30198439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer.
    Cripps C; Winquist E; Devries MC; Stys-Norman D; Gilbert R;
    Curr Oncol; 2010 Jun; 17(3):37-48. PubMed ID: 20567625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials.
    Poulose JV; Kainickal CT
    World J Clin Oncol; 2022 May; 13(5):388-411. PubMed ID: 35662989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy in head and neck cancer - scientific rationale, current treatment options and future directions.
    Rothschild U; Muller L; Lechner A; Schlösser HA; Beutner D; Läubli H; Zippelius A; Rothschild SI
    Swiss Med Wkly; 2018; 148():w14625. PubMed ID: 29756633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JAVELIN Head and Neck 100: a Phase III trial of avelumab and chemoradiation for locally advanced head and neck cancer.
    Yu Y; Lee NY
    Future Oncol; 2019 Mar; 15(7):687-694. PubMed ID: 30461306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy Advances in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Its Relationship With Human Papillomavirus.
    Wang H; Zhao Q; Zhang Y; Zhang Q; Zheng Z; Liu S; Liu Z; Meng L; Xin Y; Jiang X
    Front Immunol; 2021; 12():652054. PubMed ID: 34305889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy in head and neck cancer: aiming at EXTREME precision.
    Szturz P; Vermorken JB
    BMC Med; 2017 Jun; 15(1):110. PubMed ID: 28571578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing treatments for recurrent or metastatic head and neck squamous cell carcinoma.
    Specenier P; Vermorken JB
    Expert Rev Anticancer Ther; 2018 Sep; 18(9):901-915. PubMed ID: 29999437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
    Taberna M; Oliva M; Mesía R
    Front Oncol; 2019; 9():383. PubMed ID: 31165040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial.
    Burtness B; Bourhis JP; Vermorken JB; Harrington KJ; Cohen EE
    Trials; 2014 Nov; 15():469. PubMed ID: 25432788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).
    Cohen EEW; Bell RB; Bifulco CB; Burtness B; Gillison ML; Harrington KJ; Le QT; Lee NY; Leidner R; Lewis RL; Licitra L; Mehanna H; Mell LK; Raben A; Sikora AG; Uppaluri R; Whitworth F; Zandberg DP; Ferris RL
    J Immunother Cancer; 2019 Jul; 7(1):184. PubMed ID: 31307547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current status of systemic therapy for recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Jacob LA; Chaudhuri T; Lakshmaiah KC; Babu KG; Dasappa L; Babu M; Rudresha AH; Lokesh KN; Rajeev LK
    Indian J Cancer; 2016; 53(4):471-477. PubMed ID: 28485332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy for head and neck cancer: from recurrent/metastatic disease to (neo)adjuvant treatment in surgically resectable tumors.
    Specenier P
    Curr Opin Otolaryngol Head Neck Surg; 2021 Apr; 29(2):168-177. PubMed ID: 33605624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy for squamous cell carcinoma of the head and neck.
    Yokota T; Homma A; Kiyota N; Tahara M; Hanai N; Asakage T; Matsuura K; Ogawa T; Saito Y; Sano D; Kodaira T; Motegi A; Yasuda K; Takahashi S; Tanaka K; Onoe T; Okano S; Imamura Y; Ariizumi Y; Hayashi R;
    Jpn J Clin Oncol; 2020 Sep; 50(10):1089-1096. PubMed ID: 32776100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy for head and neck squamous cell carcinoma: current status and perspectives.
    Daste A; Larroquette M; Gibson N; Lasserre M; Domblides C
    Immunotherapy; 2024 Feb; 16(3):187-197. PubMed ID: 38126161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy in head and neck squamous cell carcinoma: An updated review.
    Parmar K; Mohamed A; Vaish E; Thawani R; Cetnar J; Thein KZ
    Cancer Treat Res Commun; 2022; 33():100649. PubMed ID: 36279709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
    Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A
    BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current Prospects of Molecular Therapeutics in Head and Neck Squamous Cell Carcinoma.
    Devaraja K
    Pharmaceut Med; 2019 Aug; 33(4):269-289. PubMed ID: 31933185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy.
    Larkins E; Blumenthal GM; Yuan W; He K; Sridhara R; Subramaniam S; Zhao H; Liu C; Yu J; Goldberg KB; McKee AE; Keegan P; Pazdur R
    Oncologist; 2017 Jul; 22(7):873-878. PubMed ID: 28533473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapies and Future Combination Strategies for Head and Neck Squamous Cell Carcinoma.
    Cristina V; Herrera-Gómez RG; Szturz P; Espeli V; Siano M
    Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31671550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 63.